Which pathology are worth shortlisting in 2026?
Four tools survived our 2026 review for clinical use: Tempus Digital Pathology for paige acquisition (aug 2025); PathAI AISight for open ims + ai platform; Proscia Concentriq for pharma r&d labs; Ibex Medical Analytics for deployed globally.
Four tools we actually recommend
Each pick wins a specific use case. The wrong question is “which is best”. The right question is “which fits my situation”. Skip past the ones not matching yours.
by Tempus AI
Niche fit· 28Paige Predict 123-biomarker pan-cancer suite, now part of Tempus AI.
NASDAQ:TEM. Most clinical-validation depth. FDA + CE-IVDR cleared modules.
- No public price on the Tempus pages.
- FDA De Novo (DEN200080) / FDA 510(k) (FullFocus viewer) / CE-IVDR
by PathAI
Competitive· 30Open IMS with AISight Dx + biopharma diagnostic services.
Vendor-agnostic IMS appeals to mixed-vendor labs. Strong biopharma R&D revenue.
- No public price. Billing period, trial and refund not stated.
- FDA 510(k)
by Proscia
Competitive· 30Used by 16/20 top pharma. $130M total funding.
IMS platform + AI marketplace. Strongest pharma R&D footprint.
- No public price. Demo request only.
- FDA 510(k) / SOC 2 Type II (vendor announcement, 2025-12-03) / ISO 27001 (vendor-stated, 2023)
by Ibex
Competitive· 32Most-deployed AI pathology platform globally.
Israeli-origin. Prostate, breast, colon focus. Broad EU + US deployments.
- No public price. Sold to laboratories and health systems on enterprise contracts.
- FDA 510(k)
What should clinicians look for when buying pathology?
The right tool depends on your workflow, your specialty, your budget, and your scale. Five criteria do most of the work narrowing your shortlist.
Workflow integration depth
How deeply does it sit inside your existing workflow? Tools that require copy-paste eventually get abandoned. Tools with native bidirectional sync into your EHR or platform stay.
HIPAA + compliance attestation
Non-negotiable for any clinical use. Look for explicit HIPAA + SOC2 + signed BAA. Free general-purpose LLMs are NOT compliant out-of-the-box.
Pricing transparency
Vendors that publish per-seat or per-encounter pricing on their site are easier to evaluate than enterprise-only quotes. If you can't get pricing without a sales call, factor that friction in.
Specialty and language fit
Performance varies materially by specialty and patient population. Aggregated reviews often look fine but mask specialty-level variance. Pilot in your own workflow before committing.
Vendor stability
This is a multi-year commitment in practice. Funding stage, leadership continuity, enterprise references, and platform partnerships matter. Pre-Series-B vendors carry more risk.
How do all 16 platforms compare side-by-side?
Pricing from vendor documentation, certifications verified against public attestations. Highlighted rows were directly evaluated by an MD on our editorial team within the past six months.
| Ref | Tool | From | Score | Compliance / EHR | Founded | Action |
|---|---|---|---|---|---|---|
| PA-001 |  Aiforia Technologies | No public price. The pricing page returns a 404. | 24/100Niche fit | CE-IVDR | — | Visit |
| PA-002 |  Aignostics | No public price. The product is sold to biopharma and research customers. | 5/100Tracked | ISO 13485ISO 27001 | — | Visit |
| PA-003 |  ContextVision | No public price. The site shows no plan, billing period or trial. | 5/100Tracked | CE mark (INIFY Prostate Screening, 2020) | — | Visit |
| PA-004 |  Deep Bio | No public price. | 16/100Tracked | — | Visit | |
| PA-005 |  DoMore Diagnostics | No public price. Per-test pricing is not published. | 5/100Tracked | CE-IVD (Histotype Px Colorectal, May 2022) | — | Visit |
| PA-006 |  Huron Technologies | No public price. Scanners are capital equipment. | 5/100Tracked | — | Visit | |
| PA-007 | No public price. Sold to laboratories and health systems on enterprise contracts. | 32/100Competitive | FDA 510(k) | — | Visit | |
| PA-008 |  Indica Labs | No public price. | 25/100Niche fit | FDA 510(k) | — | Visit |
| PA-009 |  Lumea | No public price. The site shows no plan, billing period or trial. | 20/100Niche fit | FDA 510(k) | — | Visit |
| PA-010 |  Mindpeak | No public price. | 21/100Niche fit | — | Visit | |
| PA-011 |  PathAI | No public price. Billing period, trial and refund not stated. | 30/100Competitive | FDA 510(k) | 2016 | Visit |
| PA-012 |  Proscia | No public price. Demo request only. | 30/100Competitive | FDA 510(k)SOC 2 Type II (vendor announcement, 2025-12-03)ISO 27001 (vendor-stated, 2023) | — | Visit |
| PA-013 |  Qritive | No public price. The site shows no plan, billing period or trial. | 5/100Tracked | — | Visit | |
| PA-014 | Sectra | No public price. Contact form only. | 25/100Niche fit | FDA 510(k) | — | Visit |
| PA-015 |  Tempus AI | No public price on the Tempus pages. | 28/100Niche fit | FDA De Novo (DEN200080)FDA 510(k) (FullFocus viewer)CE-IVDR | — | Visit |
| PA-016 |  Visiopharm | No public price. | 32/100Competitive | CE-IVD (IVDR)ISO 13485:2016 | — | Visit |
Scroll horizontally to see all columns.
What do clinicians ask about pathology?
Sourced from pathologists, lab directors, and KLAS digital pathology 2026 review.
Browse all questionsDeeper articles
Suki pricing in 2026: what practices and health systems actually pay
Suki publishes no price. Third parties report $299 to $399 per user per month, and $350 to $500+ on enterprise contracts, as of October 2026.
Ambience Healthcare pricing in 2026: what health systems actually pay
Ambience publishes no price and ties its fees to outcomes. Third-party estimates run about $233 to $417 per provider per month, as of October 2026.
Abridge pricing in 2026: what health systems actually pay
Abridge publishes no price. Third-party estimates run from about $208 to $600 per clinician per month, plus implementation, as of October 2026.